Triplet immuno-oncology drug combinations – the future of treating multiple cancer
The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with high unmet need.
Immune system and cancer interactions
The immune system is a highly effective host-defense system which, if effectively guided, has the potential to successfully eradicate cancers. This theory was first put forth by Thomas and Burnet in 19571 and their work on immune surveillance aided William B Coley during the first application of an immuno-oncology (IO) approach in cancer treatment.2 IO drugs have redefined the treatment paradigm for every cancer type and are now a major focus of clinical research. They also have the potential to culminate in an optimal treatment approach to significantly increase cure rates among multiple cancer indications.
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!